Sphingolipid

INTRODUCING BYOMA BODY

Retrieved on: 
Wednesday, March 13, 2024
PHA, TIME, Face, Cell, Hyperpigmentation, Science, Microbiota, Complex, Inflammation, NMF, Dermis, Red, Skin, Ceramide, Love, BLUE, Irritation, BETA, Sphingolipid, Cholesterol, Dicarboxylic acid, Gland, Itch, Cosmetics

NEW YORK, March 13, 2024 /PRNewswire/ -- BYOMA BODY is here to disrupt and democratize the bodycare category in the same way we revolutionized skincare – bringing best-in-class barrier care and skin-compatible science below the neck. This is accessible, affordable, and approachable barrier care for the rest of you – targeted, clinically efficacious, sensorial formulas for your best body.

Key Points: 
  • BYOMA Body is here to change that.
  • Skin does not have a uniform composition, so we are more likely to experience different issues on our body than on our faces.
  • BYOMA has carefully studied the science of skin – breaking down the barrier from the lipid layer to the microbiome.
  • This is a breakthrough in skin science that delivers the same level of care to your body as you show your face.

Global Lipid Nanoparticle Manufacturing Market 2023-2035: Partnerships Surge in Lipid Nanoparticle Manufacturing as Moderna Collaborates with IBM for Cutting-Edge LNPs - ResearchAndMarkets.com

Retrieved on: 
Monday, February 12, 2024
Technology, Biotechnology, Nanotechnology, Health, Molecule, CMO, Infection, Growth, RNA, Phospholipid, Liposome, Solubility, Organization, Absorption, Integration, Therapy, Type, Levidian Nanosystems, Small RNA, Ionization, DNA, Partnership, Creative Biolabs, CMOS, Permeability, Sphingolipid, CDMO, SaRNA, Dicarboxylic acid, Antigen, Research, Emergent, Acquisition, Lipid, Messenger, PEGylation, IBM, Geography, Risk, Fresenius (company), Fujifilm, Triglyceride, Element, MicroRNA, Acuitas Therapeutics, Vaccine

This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.

Key Points: 
  • This in turn will drive the market growth of lipid nanoparticle manufacturing market during the forecast period.
  • The report features an extensive study of the current market landscape, market size and future opportunities within the lipid nanoparticle manufacturing market, during the given forecast period.
  • Key takeaways of the lipid nanoparticle manufacturing (services and technologies) market report are briefly discussed below.
  • An in-depth analysis of the factors that can impact the growth of lipid nanoparticle manufacturing market.

Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote

Retrieved on: 
Monday, January 29, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mortality, Death, HSCT, Patient, Legislation, GALC, Advisory Committee, AAV, Psychosine, ESGCT, Data, Gene, DSM-IV codes, Neurodegenerative disease, Disease, Safety, Central nervous system, Sphingolipid, Physician, Krabbe disease, Cell, Human services, Parent, Nervous system, Clinical trial, Forge, Peripheral nervous system, Hematopoietic stem cell transplantation, Brain, UCBT, Pharmaceutical industry

Infantile Krabbe patients, often not diagnosed until after significant disease manifestations have occurred, typically die by the age of two if not treated by HSCT before symptoms are observed.

Key Points: 
  • Infantile Krabbe patients, often not diagnosed until after significant disease manifestations have occurred, typically die by the age of two if not treated by HSCT before symptoms are observed.
  • Previously published data have demonstrated that patients with Krabbe treated with HSCT demonstrate increased lifespan and stabilization of neurodegenerative disease in the central nervous system.
  • FBX-101, an investigational adeno-associated viral (AAV) gene therapy, has been designed to address the peripheral nerve disease not corrected by HSCT.
  • As a result, after a year of patient and foundation advocacy, Krabbe disease is again being voted on for potential inclusion on the RUSP.

Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions

Retrieved on: 
Tuesday, September 26, 2023
Cholesterol, Cayman Chemical Company, Biology, Cardiolipin, Lipid, Agonal respiration, Protein, Phospholipid, PIP, Multimedia, Sphingolipid, ANN, Cell adhesion, Vaccine, Dietary supplement, Lysophospholipid receptor

ANN ARBOR, Mich., Sept. 26, 2023 /PRNewswire-PRWeb/ -- Cayman Chemical, a leading supplier of bioactive lipids, has developed Cayman LipiDOT Strips™ as a research tool for the rapid identification of protein-lipid interactions. This new tool allows researchers to maximize the information gained from early protein-lipid interaction screening campaigns, giving researchers greater insight into protein-lipid interactions while being simple to perform, low cost, and easily completed in a single day.

Key Points: 
  • Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions.
  • This new tool allows researchers to maximize the information gained from early protein-lipid interaction screening campaigns, giving researchers greater insight into protein-lipid interactions while being simple to perform, low cost, and easily completed in a single day.
  • Cayman LipiDOT Strips™ - PIPs Plus is the first introduction to Cayman's new product group.
  • Custom biophysical characterization and structural biology solutions are also provided by Cayman to further characterize protein-lipid interactions.

Metabolon Announces Three Oral Presentations and Two Poster Presentations at the 2023 Metabolomics Society Annual Conference

Retrieved on: 
Tuesday, June 13, 2023
LC-MS/MS, Cannabinoid, Oxysterol, Molecule, QC, ECS, Nociception, ISO, Complementarity, Research, Inflammation, Appetite, PQC, Locomotion, Plasma, CLIA, Publication, Publishing, Sphingolipid, QA, Area studies, Medicine, What They Always Tell Us, Quality control, Knowledge, Memory, Medical device, Metabolomics, Metabolon, Diabetes

MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.

Key Points: 
  • MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.
  • "We are honored to present at the Metabolomics Society annual conference.
  • The presentation reports on one of the most deeply phenotyped cohort studies to date: the Qatar Metabolomics Study of Diabetes.
  • In the past year, Metabolon has launched a wide range of new targeted metabolomics panels that provide absolute quantification for important research areas.

Metabolon Announces Three Oral Presentations and Two Poster Presentations at the 2023 Metabolomics Society Annual Conference

Retrieved on: 
Tuesday, June 13, 2023
LC-MS/MS, Cannabinoid, Oxysterol, Molecule, QC, ECS, Nociception, ISO, Complementarity, Research, Inflammation, Appetite, PQC, Locomotion, Plasma, CLIA, Publication, Publishing, Sphingolipid, QA, Area studies, Medicine, What They Always Tell Us, Quality control, Knowledge, Memory, Medical device, Metabolomics, Metabolon, Diabetes

MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.

Key Points: 
  • MORRISVILLE, N.C., June 13, 2023 /PRNewswire/ -- Metabolon , Inc., the global leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced three oral presentations and two poster presentations at the 2023 Metabolomics Society annual conference taking place June 18-22 in Niagara Falls, Canada.
  • "We are honored to present at the Metabolomics Society annual conference.
  • The presentation reports on one of the most deeply phenotyped cohort studies to date: the Qatar Metabolomics Study of Diabetes.
  • In the past year, Metabolon has launched a wide range of new targeted metabolomics panels that provide absolute quantification for important research areas.

Enanta Pharmaceuticals Announces Data Presentation at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2023

Retrieved on: 
Wednesday, June 7, 2023
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, EASL, Autoimmune hepatitis, Medication, Toronto Congress Centre, Sphingolipid, Viral, Poster, European Association for the Study of the Liver, Pharmaceutical industry, Liver

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 being held June 21 – 24, 2023 in Vienna, Austria at the Messe Wien Exhibition Congress Centre.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that preclinical data from Enanta’s out-licensing portfolio has been accepted for a poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress 2023 being held June 21 – 24, 2023 in Vienna, Austria at the Messe Wien Exhibition Congress Centre.
  • In the poster, Enanta’s HSD17B13 inhibitors, which have previously been shown to be anti-inflammatory in vivo with modulation of sphingolipids, were evaluated in a mouse model of autoimmune hepatitis for anti-inflammatory and hepatoprotective effects.
  • The full scientific program for The International Liver Congress 2022, as well as the abstracts, can be found at https://www.easlcongress.eu/ .

Metabolon Expands Inflammation Portfolio with Targeted Panels for Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation

Retrieved on: 
Tuesday, January 17, 2023
Disease, Multiple sclerosis, Neurodegeneration, Swelling, Parkinson's disease, Inflammation, Broadband, Huntington's disease, Lipid, Organic acid, Learning, Portfolio, Fertility, Chronic pain, Precision medicine, Degenerative disease, Biomarker, Pregnancy, Dermatitis, Metabolomics, Neuro, Appetite, Research, Acquisition, Alzheimer's disease, Pain, Vaccine, Pharmaceutical industry, Sphingolipid, Metabolon, Cannabinoid

MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon's Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.

Key Points: 
  • The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation.
  • Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation.
  • The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation.
  • The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.

Metabolon Expands Inflammation Portfolio with Targeted Panels for Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation

Retrieved on: 
Tuesday, January 17, 2023
Disease, Multiple sclerosis, Neurodegeneration, Swelling, Parkinson's disease, Inflammation, Broadband, Huntington's disease, Lipid, Organic acid, Learning, Portfolio, Fertility, Chronic pain, Precision medicine, Degenerative disease, Biomarker, Pregnancy, Dermatitis, Metabolomics, Neuro, Appetite, Research, Acquisition, Alzheimer's disease, Pain, Vaccine, Pharmaceutical industry, Sphingolipid, Metabolon, Cannabinoid

MORRISVILLE, N.C., Jan. 17, 2023 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of research, diagnostic, therapeutic development, and precision medicine applications, today announced a significant expansion of its Inflammation Portfolio with the launch of new Targeted Panels studying Cannabinoids, Sphingolipids, and Lipid Mediators of Inflammation. The Portfolio also includes the recently launched Oxysterols Targeted Panel. Metabolon's Inflammation Portfolio detects and provides deeper insights into a wide range of known bioactive mediators of inflammation for the prediction, early detection, and monitoring of disease states, including chronic pain, neuro-inflammatory disease, neurodegeneration, and cardiovascular diseases.

Key Points: 
  • The Metabolon Sphingolipid Targeted Panel measures changes in 61 lipid species across five lipid classes with strong links to inflammation.
  • Lipid mediators of inflammation are a group of molecules involved in immune response and inflammation.
  • The balanced production and regulation of lipid mediators of inflammation are important for maintaining normal immune function and preventing chronic inflammation.
  • The Metabolon Lipid Mediators of Inflammation Targeted Panel detects 58 analytes associated with metabolic consequences of widespread inflammatory disease to identify biomarkers and their quantitative changes.

Forge Biologics Announces Updated Positive Clinical Data in RESKUE, a Novel Phase 1/2 Gene Therapy Trial for Patients with Krabbe Disease

Retrieved on: 
Tuesday, October 11, 2022
Children, Biotechnology, Manufacturing, Health, Pharmaceutical, Research, Other Manufacturing, Genetics, Consumer, Science, Clinical Trials, CA, HSCT, Congress, ESGCT, CSF, Hope, Diagnosis, Locomotion, Krabbe disease, Lists of diseases, Peripheral nervous system, Cell, CGMP, Patient, Gene, Mesa, Sphingolipid, Dementia, Peripheral neuropathy, Multimedia, White matter, Clinical trial, European Society of Gene and Cell Therapy, Nerve, Psychosine, PNS, Hearing loss, AAV, Cerebrospinal fluid, Degenerative disease, Irritability, GALC, CEO, Hematopoietic stem cell transplantation, Incidence, Death, Safety, Natural history, CNS, M.D, Neurodegeneration, Brain, Plasma, ARM, Infant, Central nervous system, Nervous system, Pharmaceutical industry, Vaccine, Hearth, Krabbe, Forge

Clinical data support preclinical observations that this gene therapy approach after HSCT may lessen many of the immune challenges previously observed with systemic AAV gene delivery and may create a safer environment for gene replacement.

Key Points: 
  • Clinical data support preclinical observations that this gene therapy approach after HSCT may lessen many of the immune challenges previously observed with systemic AAV gene delivery and may create a safer environment for gene replacement.
  • Findings also support this novel approach for extending the delivery of gene replacement strategies to target metabolic diseases amenable to HSCT.
  • Krabbe disease is characterized by mutations in the GALC gene which lead to loss of motor function.
  • RESKUE a Phase 1/2 clinical trial to investigate the safety and efficacy of FBX-101 in patients with Infantile Krabbe disease.